Although clinical evidence supports improved overall survival rates across multiple cancer types with camrelizumab, unexpected binding of camrelizumab to VEGFR2 has been reported and may correlate with the side effects of capillary hemangiomas usually observed in clinical studies with camrelizumab (30). The gene discussed is KDR; the disease is cancer.